• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792).
  
• Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=26428435; PubMed=33460449).
  
• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
  

PubMed=10079
Schlesinger H.R., Gerson J.M., Moorhead P.S., Maguire H., Hummeler K.
Establishment and characterization of human neuroblastoma cell lines.
Cancer Res. 36:3094-3100(1976)

DOI=10.1016/B978-0-12-008304-6.50015-4
Biedler J.L., Meyers M.B., Spengler B.A.
Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.
(In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983)

PubMed=2777647; DOI=10.1016/0360-3016(89)90111-9
Schwachofer J.H.M., Crooijmans R.P.M.A., van Gasteren J.J.M., Hoogenhout J., Jerusalem C.R., Kal H.B., Theeuwes A.G.M.
Repair of sublethal damage in two human tumor cell lines grown as multicellular spheroids.
Int. J. Radiat. Oncol. Biol. Phys. 17:591-595(1989)

PubMed=1992541
Schwachofer J.H.M., Crooijmans R.P.M.A., Hoogenhout H., Kal H.B., Schaapveld R.Q.J., Wessels J.
Differences in repair of radiation induced damage in two human tumor cell lines as measured by cell survival and alkaline DNA unwinding.
Strahlenther. Onkol. 167:35-40(1991)

DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=21822310; DOI=10.1038/onc.2011.317
Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V., Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R., Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U., Debiec-Rychter M., Schaefer K.-L., de Alava E.
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Oncogene 31:1287-1298(2012)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020
Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P., Schmidt T., Szuhai K., Hogendoorn P.C.W.
CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Eur. J. Cancer 51:2624-2633(2015)

PubMed=33460449; DOI=10.1002/ijc.33474
Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J., Nagel S., Steenpass L., Becker J.
Cross-contamination meets misclassification: awakening of CHP-100 from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.
Int. J. Cancer 148:2608-2613(2021)